61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A
Continued favorable safety and tolerability profile consistent with the IL-23p19 class
ORKA-001 on track to advance into Phase 3 trials in 1H 2027
52-week EVERLAST-A results on track for
ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027
Management to host conference call today at
“We are incredibly pleased with the remarkable profile of ORKA-001 observed to date, with highly consistent results achieved across EVERLAST-B and EVERLAST-A. These results further solidify our confidence that ORKA-001 could become the preferred medicine for psoriasis, with high rates of complete skin clearance, a favorable safety profile, and potential for dosing once to twice per year,” said
“These results suggest ORKA-001 is likely to be the most effective IL-23-targeting biologic to date,” said
EVERLAST-B is a randomized, double-blind, placebo-controlled Phase 2b trial evaluating the safety, efficacy, and pharmacokinetics of ORKA-001 in patients with moderate-to-severe PsO. The trial is being conducted across 36 sites in
Efficacy
Efficacy increased in a dose-dependent manner across ORKA-001 treatment groups, with the high-dose (600 mg) group outperforming both lower dose groups on complete skin clearance. 61% of patients in the high-dose group achieved the primary endpoint of PASI 100 at Week 16, compared to 0% of patients receiving placebo (p<0.0001). The ORKA-001 high-dose group demonstrated high response rates across secondary endpoints, including 86% of patients achieving PASI 90 and IGA 0/1, consistent with the results observed in EVERLAST-A.
| Week 16 | Placebo (N=47) | Low dose (N=47) | Mid dose (N=47) | High dose (N=46) |
| PASI 100 | 0% | 43% | 44% | 61% |
| PASI 90 | 0% | 70% | 85% | 86% |
| IGA 0/1 | 0% | 74% | 85% | 86% |
Safety
ORKA-001 continues to be well tolerated, with a safety profile consistent with the IL-23p19 class. The overall rate of treatment-emergent adverse events (TEAEs) was comparable across groups, with 39% of patients in the high-dose group experiencing at least one TEAE, versus 43% of participants receiving placebo. The only TEAEs occurring in =5% of patients treated with ORKA-001 were upper respiratory tract infection and headache, occurring at rates similar to those seen with approved IL-23 inhibitors. No dose-dependent trends in adverse events were observed across ORKA-001 treatment groups, and no injection-site reactions occurred in any patients who received ORKA-001.
| Week 0-16 | Placebo (N=47) | Low dose (N=47) | Mid dose (N=47) | High dose (N=46) | All ORKA-001 (N=140) |
| =1 TEAE, n (%) | 20 (43%) | 22 (47%) | 28 (60%) | 18 (39%) | 68 (49%) |
| =1 serious TEAE, n (%) | 2 (4%) | 1 (2%) | 2 (4%) | - | 3 (2%) |
| =1 severe TEAE, n (%) | 2 (4%) | 1 (2%) | 2 (4%) | - | 3 (2%) |
| Discontinuation due to TEAE, n (%) | 1 (2%) | 1 (2%) | 1 (2%) | - | 2 (1%) |
| Most frequent TEAEs, n (%) | |||||
| Upper respiratory tract infection | 4 (9%) | 5 (11%) | 9 (19%) | 6 (13%) | 20 (14%) |
| Headache | 1 (2%) | 2 (4%) | 3 (6%) | 3 (7%) | 8 (6%) |
| Injection site reactions, n (%) | 1 (2%) | - | - | - | - |
No serious TEAEs occurred in the high-dose group. Serious TEAEs occurring in the other groups were kidney stones, miscarriage, psoriasis, substance-induced psychotic disorder, and syncope following a blood draw and jaw fracture. None were considered treatment related.
Upcoming Milestones for ORKA-001
Based on the results from the EVERLAST clinical program, the company intends to discuss Phase 3 plans with regulatory authorities. Pending results from those discussions, Oruka plans to initiate Phase 3 trials of ORKA-001 in moderate-to-severe PsO in the first half of 2027 with the high dose (600 mg). In addition, Oruka expects to share 52-week results from EVERLAST-A in
Webcast Details
Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin today at
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Forward-Looking Statements
Certain statements in this press release, other than statements of historical fact, are “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, efficacy, safety, tolerability, durability of response and dosing profile of ORKA-001; the potential for ORKA-001 to provide durable disease control with infrequent dosing; the planned conduct, progress, timing and results of the EVERLAST-A and EVERLAST-B trials; and the anticipated timing of clinical data readouts and ORKA-001 Phase 3 trial commencement. These forward-looking statements are based on Oruka’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law.
Investor Contact:
Alan Lada
(650) 606-7911
alan.lada@orukatx.com
Source: Oruka Therapeutics, Inc.
